PMID- 26268058
OWN - NLM
STAT- MEDLINE
DCOM- 20151022
LR  - 20221207
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 54
IP  - 4
DP  - 2015 Apr
TI  - [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in 
      newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
PG  - 307-12
AB  - OBJECTIVE: To evaluate the efficacy and safety of human glucagon-like peptide-1 
      analogue liraglutide in newly diagnosed type 2 diabetes mellitus (T2DM) with 
      glycosylated hemoglobin A1c (HbA1c) > 9%. METHODS: This was an open-labelled, 
      randomized, parallel-group, treat-to-target trial. Newly diagnosed T2DM patients 
      with HbA1c > 9% were enrolled. These patients were treated with metformin with 
      repaglinide and randomized to receive once-daily liraglutide (LIRA, n=25) or the 
      insulin glargine (IGla, n=24) at bedtime. Efficacy and safety were assessed and 
      compared after 18-month treatment. RESULTS: (1) Compared with the baseline, 
      patients with LIRA had significantly reduced mean body weight,BMI and waist 
      circumference (P < 0.01), whereas, the above indexes were increased (P < 0.01) in 
      patients treated with IGla. (2) After 18 months of treatment, fasting plasma 
      glucose (FPG), 2-hour plasma glucose after a 75g oral glucose load (2hPG) and 
      HbA1c were significantly improved in all patients (P < 0.01), with 2hPG, mean 
      blood glucose (MBG), the largest amplitude of glycemic excursions (LAGE), mean 
      amplitude of glycemic excursions (MAGE) were significantly lower in LIRA group 
      than in IGla group (all P < 0.05). (3) HOMA-IR decreased in both groups (P < 
      0.05). However, DeltaI30/DeltaG30, AUCCP180 and Matsuda index were only significantly 
      increased in patients treated with LIRA (respectively, 4.88 +/- 1.55 vs 7.60+/-1.91, 
      9.23 +/- 2.66 vs 13.18 +/- 2.72, 39.28 +/- 20.35 vs 54.64 +/- 23.34, all P < 0.01), while 
      HOMA-IR reduced (4.41 +/- 1.58 vs 3.52 +/- 1.44, P < 0.05). But in IGla group only 
      HOMA-IR was reduced (4.92 +/- 1.84 vs 4.57 +/- 1.80, P < 0.05). The index of 
      DeltaI30/DeltaG30, AUCCP180 and Matsuda index in LIRA group are higher than those of 
      indexes in IGla group(respectively, 7.60 +/- 1.91 vs 4.18 +/- 1.00, 13.18 +/- 2.72 vs 
      10.53 +/- 2.68,54.64 +/- 23.34 vs 41.65 +/- 17.84, all P < 0.05), while HOMA-IR is 
      lower (3.52 +/- 1.44 vs 4.57 +/- 1.80, P< 0.05). (4) The rate of HbA1c </= 6.5% and the 
      dosages of oral anti-diabetic drugs in LIRA group were significantly better than 
      that in IGla group. (5) No significant differences were observed in hypoglycemic 
      episodes and adverse events between two groups. CONCLUSION: It seems that 
      liraglutide is superior to insulin glargine in newly diagnosed T2DM patients with 
      HbA1c > 9% in improving beta-cell function, insulin sensitivity and glucose 
      homeostasis.
FAU - Yan, Lihui
AU  - Yan L
FAU - Wang, Shaozhen
AU  - Wang S
AD  - Department of Gastroenterology, Metabolic Disease Hospital, Tianjin Medical 
      University, Key Laboratory of Hormones and Development, Ministry of Health, 
      Tianjin 300070, China; Email: yanlihui1981@163.com.
FAU - Chen, Pin
AU  - Chen P
FAU - Chen, Chen
AU  - Chen C
FAU - Shao, Zhulin
AU  - Shao Z
FAU - Xu, Xiangjin
AU  - Xu X
FAU - Huang, Qin
AU  - Huang Q
AD  - Department of Endocrinology, Changhai Hospital Affiliated of Second Military 
      Medical University, Shanghai 200433, China; Email: qxinyi1220@163.com.
LA  - chi
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin, Long-Acting)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Blood Glucose/drug effects/*metabolism
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy
MH  - Glucagon-Like Peptide 1/administration & dosage/adverse effects/analogs & 
      derivatives/therapeutic use
MH  - Glycated Hemoglobin/analysis/*metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects
MH  - Insulin Glargine
MH  - Insulin, Long-Acting/*administration & dosage/therapeutic use
MH  - Liraglutide
MH  - Metformin
MH  - Treatment Outcome
EDAT- 2015/08/14 06:00
MHDA- 2015/10/23 06:00
CRDT- 2015/08/14 06:00
PHST- 2015/08/14 06:00 [entrez]
PHST- 2015/08/14 06:00 [pubmed]
PHST- 2015/10/23 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2015 Apr;54(4):307-12.